Navacaprant Explained

Navacaprant (developmental code names include BTRX-335140, BTRX-140, CYM-53093, NMRA-335140, and NMRA-140), is a selective κ-opioid receptor antagonist which is under development for the treatment of major depressive disorder.^{[1] [2] [3]} As of December 2023, navacaprant is in phase 3 clinical trials for this indication.^[4]

See also

• κ-Opioid receptor § Antagonists
• List of investigational antidepressants

External links

• BTRX 335140 - AdisInsight

Notes and References

1. Web site: BlackThorn Therapeutics Advances Phase 2 Clinical Development for Selective KOR Antagonist, BTRX-140, in Neuropsychiatric Disorders. BlackThorn Therapeutics. en. 2020-01-25. 2020-01-25. https://web.archive.org/web/20200125221757/https://www.blackthornrx.com/publications/blackthorn-therapeutics-advances-phase-2-clinical-development-for-selective-kor-antagonist-btrx-140-in-neuropsychiatric-disorders/. dead.
2. Web site: BTRX 335140 - AdisInsight. adisinsight.springer.com. 2020-01-25.
3. Guerrero M, Urbano M, Kim EK, Gamo AM, Riley S, Abgaryan L, Leaf N, Van Orden LJ, Brown SJ, Xie JY, Porreca F, Cameron MD, Rosen H, Roberts E . Design and Synthesis of a Novel and Selective Kappa Opioid Receptor (KOR) Antagonist (BTRX-335140) . J. Med. Chem. . 62 . 4 . 1761–1780 . February 2019 . 30707578 . 6395531 . 10.1021/acs.jmedchem.8b01679 .
4. A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effects of Oral NMRA-335140 Versus Placebo in Participants With Major Depressive Disorder . Neumora Therapeutics, Inc. . 2024-02-20 . clinicaltrials.gov . NCT06058039.